Establishing a therapeutic index for the inhaled corticosteroids: Part I. Pharmacokinetic/pharmacodynamic comparison of the inhaled corticosteroids

Journal of Allergy and Clinical Immunology

Volumn 102, Issue 4 SUPPL., 1998, Pages

  Kelly, H William ^a  

^a UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

Clearance; Clinical trials; Cortieosteroids; Dose response relationship; Inhalers; Pharmacokinectics

Indexed keywords

BECLOMETASONE DIPROPIONATE; CORTICOSTEROID; FLUNISOLIDE; GLUCOCORTICOID RECEPTOR; TRIAMCINOLONE;

ASTHMA; BRONCHUS HYPERREACTIVITY; CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG COST; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; INHALATIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ASTHMA; BIOLOGICAL AVAILABILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS;

EID: 0031794756     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-6749(98)70004-1     Document Type: Article

References (113)

1. Barnes PJ. Inhaled glucocorticoids for asthma. N Engl J Med 1995;332:868-75.
2. National Asthma Education Program. Expert Panel Report: guidelines for the diagnosis and management of asthma. Bethesda (MD): NIH/National Heart, Lung, and Blood Institute, 1991. Publication No. 91-3042.
3. Global Initiative for Asthma: Global Strategy for Asthma Management and Prevention. NHLBI/WHO Workshop Report, March 1993. Rev ed. Washington [DC]: NIH/National Heart, Lung, and Blood Institute, January 1995. Publication No. 95-3659.
4. National Asthma Education and Prevention Program Expert Panel Report 2: guidelines for the diagnosis and management of asthma. Bethesda(MD):NIH/National Heart, Lung, and Blood Institute, April 1997. Publication NO. 97-4051.
5. Kamada AK, Szefler SJ, Martin RJ, Boushey HA, Chinchilli VM, Drazen JM, et al. Issues in the use of inhaled glucocorticoids. Am J Respir Crit Care Med 1996;153:1739-48.
6. Lipworth BJ. Airway and systemic effects of inhaled corticosteroids in asthma: dose response relationship. Pulm Pharmacol 1996;9:19-27.
7. Pedersen S, O'Byrne P. A comparison of the efficacy and safety of inhaled corticosteroids in asthma. Allergy 1997;52(suppl 39):1-34.
8. Barnes PJ. Mechanisms of action of glucocorticoids in asthma. Am J Respir Crit Care Med 1996;154(suppl):S21 -7.
9. Jusko WJ. Corticosteroid pharmacodynamics: models for a broad array of receptor-mediated pharmacologic effects. J Clin Pharmacol 1990;30:303-10.
10. Derendorf H, Hochhaus G, Möllmann H, Barth J, Krieg M, Tunn S, et al. Receptor-based pharmacokinetic-pharmacodynamic analysis of corticosteroids. J Clin Pharmacol 1993;33:115-23.
11. Dahlberg E, Thalén A, Brattsand R, Gustafsson J- Å, Johansson U, Roempke K, et al. Correlation between chemical structure, receptor binding, and biological activity of some novel, highly active, 16α, 17α-acetal-substituted glucocorticoids. Mol Pharmacol 1984;25:70-8.
12. Johnson M. Pharmacodynamics and pharmacokinetics of inhaled glucocorticoids. J Allergy Clin Immunol 1996;97:169-76.
13. Brattsand R. What factors determine anti-inflammatory activity and selectivity of inhaled steroids? Eur Respir Rev 1997;7:356-61.
14. Högger P, Rohdewald P. Binding kinetics of fluticasone propionate to the human glucocorticoid receptor. Steroids 1994;59:597-602.
15. Hochhaus G, Möllmann H, Derendorf H, Gonzalez-Rothi RJ. Pharmacokinetic/pharmacodynamic aspects of aerosol therapy using glucocorticoids as a model. J Clin Pharmacol 1997;37:881-92.
16. Derendorf H. Pharmacokinetic and pharmacodynamic properties of inhaled corticosteroids in relation to efficacy and safety. Respir Med 1997;91(suppl A):22-8.
17. Kelly HW. Comparison of inhaled corticosteroids. Ann Pharmacother 1998;32:220-32.
18. McKenzie AW, Stoughton RB. Method for comparing percutaneous absorption of steroids. Arch Dermatol 1962;86:611-4.
19. Brattsand R, Thalén A, Roempke K, Kallstrom L, Gruvstad E. Development of new glucocorticoids with a very high ratio between topical and systemic activities. Eur J Respir Dis 1982;63(suppl 122):62-73.
20. Phillipps GH. Structure-activity relationships of topically active steroids: the selection of fluticasone propionate. Respir Med 1990;84(suppl A):19-23.
21. English AF, Neate MS, Quint DJ, Sareen M. Biological activities of some corticesteroids used in asthma (abstract). Am J Respir Crit Care Med 1994;149(suppl):A212.
22. Andersson N, Klint S, Randwall G, Wirén J-E. Equipotency of budesonide and fluticasone propionate in the vasoconstriction assay (abstract). Am J Respir Crit Care Med 1994;149(suppl):A467.
23. Johansson S-A, Andersson K-E, Brattsand R, Gruvstad E, Hedner P. Topical and systemic glucocorticoid potencies of budesonide, beclomethasone dipropionate and prednisolone in man. Eur J Respir Dis 1982;63(suppl 122):74-82.
24. Kam JC, Szefler SJ, Surs W, Sher ER, Leung DYM. Combination of IL-2 and IL-4 reduces glucocorticoid receptor-binding affinity and T-cell response to glucocorticoids. J Immunol 1993;151:3460-6.
25. Spahn JD, Leung DYM, Surs W, Harbeck RJ, Nimmagadda S, Szefler SJ. Reduced glucocorticoid binding affinity in asthma is related to ongoing allergic inflammation. Am J Respir Crit Care Med 1995;151:1709-14.
26. Adcock IM. Steroid resistance in asthma: molecular mechanisms. Am J Respir Crit Care Med 1996;154(suppl):S58-61.
27. Jenner WN, Kirkham DJ. Immunoassay of beclomethasone 17,21-dipropionate and metabolites. In: Reid R, Robinson JD, Wilson ID, editors. Bioanalysis of drugs and metabolites. Plenem Publishing Corporation, New York; 1988. P. 77-86.
28. Falcoz C, Kirby SM, Smith J, Olsson P, Ventresca GP. Pharmacokinetics and systemic exposure of inhaled beclomethasone dipropionate. Eur Respir J 1996;9(suppl 23):162s.
29. Rohdewald P, Rehder S. Plasma levels of beclomethasone dipropionate (BDP) and its 17-monopropionate metabolite (17-BMP) following BDP inhalation (abstract). Eur Respir J 1994;7(suppl 18):382s.
30. Ryrfeldt Å, Andersson P, Edsbäcker S, Tonnesson M, Davies D, Pauwels R. Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. Eur J Respir Dis 1982;63(suppl 122):86-95.
31. Edsbäcker S, Andersson K-E, Ryrfeldt Å. Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man. Eur J Clin Pharmacol 1985;29:477-81.
32. Thorsson L, Edsbäcker S, Conradson T-B. Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler P-MDI. Eur Respir J 1994;7:1839-44.
33. Ryrfeldt Å, Edsbäcker S, Pauwels R. Kinetics of the epimeric glucocorticoid budesonide. Clin Pharmacol Ther 1984;35:525-30.
34. Chaplin MD, Rooks W II, Swenson EW, Cooper WC, Nerenberg C, Chu NI. Flunisolide metabolism and dynamics of a metabolite. Clin Pharmacol Ther 1980;27:402-13.
35. Möllmann H, Derendorf H, Barth J, Meibohm B, Wagner M, Krieg M, et al. Pharmacokinetic/pharmacodynamic evaluation of systemic effects of flunisolide after inhalation. J Clin Pharmacol 1997;37:893-903.
36. Mackie AE, Ventresca GP, Fuller RW, Bye A. Pharmacokinetics of intravenous fluticasone propionate in healthy subjects. Br J Clin Pharmacol 1996;41:539-42.
37. Thorsson L, Dahlström K, Edsbäcker S, Källén A, Paulson J, Wirén J-E. Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects. Br J Clin Pharmacol 1997;43:155-61.
38. Möllmann H, Rohdewald P, Schmidt EW, Salomon V, Derendorf H. Pharmacokinetics of triamcinolone acetonide and its phosphate ester. Eur J Clin Pharmacol 1985;29:85-9.
39. Rohatagi S, Hochhaus G, Mollman H, Barth J, Galia E, Erdmann M, et al. Pharmaco kinetic and pharmacodynamic evaluation of triamcinolone acetonide after intravenous, oral, and inhaled administration. J Clin Pharmacol 1995;35:1187-93.
40. Brown PH, Blundell G, Greening AP, Crompton GK. Do large volume spacer devices reduce the systemic effects of high dose inhaled corticosteroids? Thorax 1990;45:736-9.
41. Selroos O, Halme M. Effect of a volumatic spacer and mouth rinsing on systemic absorption of inhaled corticosteroids from a metered dose inhaler and dry powder inhaler. Thorax 1991;46:891-4.
42. Brown PH, Matusiewicz SP, Shearing C, Tibi L, Greening AP, Crompton GK. Systemic effects of high dose inhaled steroids: comparison of beclomethasone dipropionate and budesonide in healthy subjects. Thorax 1993;48:967-73.
43. Hochhaus G, Gonzalez-Rothi RJ, Lukyanov A, Derendorf H, Schreier H, Dalla Costa T. Assessment of glucocorticoid lung targeting by exvivo receptor binding studies in rats. Pharm Res 1995;12:134-7.
44. Gonzales-Rothi RJ, Suarez S, Hochhaus G, Schreier H, Lukyanov A, Derendorf H, et al. Pulmonary targeting of liposomal triamcinolone acetonide phosphate. Pharm Res 1996;13:1699-703.
45. Davies B. A comparison of beclomethasone dipropionate and budesonide in the treatment of asthma. Br J Clin Pharmacol 1993;47:87-93.
46. Lipworth BJ. New perspectives on inhaled drug delivery and systemic bioactivity (editorial). Thorax 1995;50:105-10.
47. Thorsson L. Influence of inhaler systems on systemic availability, with focus on inhaled corticosteroids. J Aerosol Med 1995;8(suppl 3):S-29-36.
48. Pauwels R, Newman S, Borgström L. Airway deposition and airway effects of antiasthma drugs delivered from metered-dose inhalers. Eur Respir J 1997;10:2127-38.
49. Newman SP. Aerosol deposition considerations in inhalation therapy. Chest 1985;88(suppl):152S-60S.
50. Chaplin MD, Cooper WC, Segre EJ, Oren J, Jones RE, Nerenberg C. Correlation of flunisolide plasma levels to eosinopenic response in humans. J Allergy Clin Immunol 1980;65:445-53.
51. Borgström L, Bondesson E, Morén F, Trofast E, Newman SP. Lung deposition of budesonide inhaled via Turbuhaler: a comparison with terbutaline sulphate in normal subjects. Eur Respir J 1994;7:69-73.
52. Physician's Desk Reference. 52nd ed. Montvale (NJ): Medical Economics Co; 1998. p. 1027-30.
53. Bisgaard H. Delivery of inhaled medication to children. J Asthma 1997;34:443-67.
54. O'Callaghan C, Cant M, Robertson C. Delivery of beclomethasone dipropionate from a spacer device: what dose is available for inhalation? Thorax 1994;49:961-4.
55. Gross G, Vanden Bürgt J, Donnell D, Amies M, Stampone P. New formulation inhaled steroid achieves equivalent peak flow control with half the daily dose in moderate asthmatics (abstract). Eur Respir J 1996;9(suppl 23):255s-6s.
56. Leach CL, Davidson P, Vanden Burgt J, Boudreau R. Breath-actuated MDI delivers 60% airway deposition with a new CFC-free beclomethasone formulation (abstract). Eur Respir J 1996;9(suppl 23):255s.
57. Harrison L, Soria I, Machacek J, Jacobson J, Purrington A, Cline A, et al. Beclomethasone pharmacokinetics in asthmatics given CFC and CFC-free inhalers (abstract). Eur Respir J 1996;9(suppl 23):256s.
58. Davies RJ, Donnell D. HFA-beclomethasone (BDP) extrafine aerosol improves therapeutic index (abstract). Thorax 1997;52(suppl 6):A58.
59. Fuller R. The Diskus: a new multi-dose powder device-efficacy and comparison with Turbuhaler. J Aerosol Med 1995;8(suppl 2):11-7.
60. Olsson B. Aerosol particle generation from dry powder inhalers: can they equal pressurized metered dose inhalers? J Aerosol Med 1995;8(suppl 3):S-13-8.
61. Hill LS, Slater AL. A comparison of the performance of two modern multidose dry powder asthma inhalers. Respir Med 1998;92:105-10.
62. Pedersen S, Hansen OR, Fuglsang G. Influence of inspiratory flow rate upon the effect of a turbuhaler. Arch Dis Child 1990;65:308-19.
63. Devadason SG, Everard ML, MacEarlan C, Roller C, Summers QA, Swift P, et al. Lung deposition from the Turbuhaler in children with cystic fibrosis. Eur Respir J 1997;10:2023-8.
64. Kerstjens HAM, Brand PLP, de Jong PM, Koëter GH, Postma DS. Influence of treatment on peak expiratory flow and its relation to airway hyperresponsiveness and symptoms. Thorax 1994;49:1109-15.
65. Kraan J, Koëter GH, van der Mark ThW, Boorsma M, Kukler J, Sluiter HJ, et al. Dosage and time effects of inhaled budesonide on bronchial hyperreactivity. Am Rev Respir Dis 1988;137:44-8.
66. Juniper EF, Kline PA, Vanzieleghem MA, Ramsdale EH, O'Byrne PM, Hargreave FE. Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics. Am Rev Respir Dis 1990;42:832-6.
67. Haley KJ, Drazen JM. Inflammation and airway function in asthma: what you see is not necessarily what you get (editorial). Am J Respir Crit Care Med 1998;157:1-3.
68. Crimi E, Spanevello A, Neri M, Ind PW, Rossi GA, Brusasco V. Dissociation between airway inflammation and airway hyperresponsiveness in allergic asthma. Am J Respir Crit Care Med 1998;157:4-9.
69. Robinson DS, Geddes DM. Inhaled corticosteroids: benefits and risks. J Asthma 1996;33:5-16.
70. Pedersen S, Hansen OR. Budesonide treatment of moderate and severe asthma in children: a dose-response study. J Allergy Clin Immunol 1995;95:29-33.
71. Freezer NJ, Croasdell H, Doull IJM, Holgate ST. Effect of regular inhaled beclomethasone on exercise and methacholine airway responses in school children with recurrent wheeze. Eur Respir J 1995;8:1488-93.
72. Toogood JH, Andreou P, Baskerville J. A methodological assessment of diurnal variability of peak flow as a basis for comparing different inhaled steroid formulations. J Allergy Clin Immunol 1996;98:555-62.
73. Haahtela T, Järvinen M, Kava T, Kiviranta K, Koskinen S, Lehtonen K, et al. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. N Engl J Med 1994;331:700-5.
74. Juniper EF, Kline PA, Vanzieleghem MA, Hargreave FE. Reduction of budesonide after a year of increased use: a randomized controlled trial to evaluate whether improvements in airway responsiveness and clinical asthma are maintained. J Allergy Clin Immunol 1991;87:483-9.
75. Spahn JD, Landwehr LP, Nimmagadda S, Surs W, Leung DYM, Szefler SJ. Effects of glucocorticoids on lymphocyte activation in patients with steroid-sensitive and steroid-resistant asthma. J Allergy Clin Immunol 1996;98:1073-9.
76. Salmeron S, Guerin J-C, Godard P, Renon D, Henry-Amar M, Duroux P, et al. High doses of inhaled corticosteroids in unstable chronic asthma: a multicenter, double-blind, placebo-controlled study. Am Rev Respir Dis 1989;140:167-71.
77. Waalkens HJ, van Essen-Zandvliet EE, Hughes MD, Gerritsen J, Duiverman EJ, Knol K, et al. Cessation of long-term treatment with inhaled corticosteroid (budesonide) in children with asthma results in deterioration. Am Rev Respir Dis 1993;148:1252-7.
78. Agertoft L, Pedersen S. Importance of the inhalation device on the effect of budesonide. Arch Dis Child 1993;69:130-3.
79. Toogood JH, White FA, Baskerville JC, Fraher LJ, Jennings B. Comparison of the antiasthmatic, oropharyngeal, and systemic glucocorticoid effects of budesonide administered through a pressurized aerosol plus spacer or the Turbuhaler dry powder inhaler. J Allergy Clin Immunol 1997;99:186-93.
80. Engel T, Heinig JH, Mailing HJ, Scharling B, Nikander K, Madsen F. Clinical comparison of inhaled budesonide delivered either via pressurized metered dose inhaler or Turbuhaler. Allergy 1989;44:220-5.
81. Agertoft L, Pedersen S. A randomized, double-blind dose reduction study to compare the minimal effective dose of budesonide Turbuhaler and fluticasone propionate Diskhaler. J Allergy Clin Immunol 1997;99:773-80.
82. Dahl R, Lundback B, Malo J-L, Mazza J, Nieminen MM, Saarelainen P, et al. A dose-ranging study of fluticasone propionate in adult patients with moderate asthma. Chest 1993;104:1352-8.
83. Chervinsky P, van As A, Bronsky EA, Dockhorn R, Noonan M, LaForce C, et al. Fluticasone propionate aerosol for the treatment of adults with mild to moderate asthma. J Allergy Clin Immunol 1994;94:676-83.
84. Leblanc P, Mink S, Keistinen T, Saarelainen PA, Ringdal N, Payne SL. A comparison of fluticasone propionate 200 mg/day with beclomethasone dipropionate 400 mg/day in adult asthma. Allergy 1994;49:380-5.
85. Gustafsson P, Tsanakas J, Gold M, Primhak R, Radford M, Gillies E. Comparison of the efficacy and safety of inhaled fluticasone propionate 200 μg/day with inhaled beclomethasone dipropionate 400 μg/day in mild and moderate asthma. Arch Dis Child 1993;69:206-11.
86. Pauwels RA, Demedts MG, Yernault JC, Geusens P, Roosens WA. Comparison of long-term safety and efficacy of fluticasone propionate and beclomethasone dipropionate in combination with salmeterol in patients with moderate to severe asthma (abstract). Am J Respir Crit Care Med 1995;151:A276.
87. -1) administered by pressurized inhaler. Respir Med 1993;87:609-20.
88. Bootsma GP, Dekhuijzen PNR, Festen J, van Herwaarden CLA. Comparison of fluticasone propionate and beclomethasone dipropionate on direct and indirect measurements of bronchial hyperresponsiveness. ATS 1995;B24: poster A41.
89. Barnes NC, Marone G, Di Maria GU, Visser S, Utama I, Payne SL. A comparison of fluticasone propionate, 1 mg daily, with beclomethasone dipropionate, 2 mg daily, in the treatment of severe asthma. Eur Respir J 1993;6:877-84.
90. Williams J. Efficacy and ease of use of the fluticasone propionate multidose inhaler compared with the budesonide reservoir powder device in asthmatic children (abstract). Eur Respir J 1995;8(suppl 19):469S.
91. Langdon CC, Thompson J. A multicentre study to compare the efficacy and safety of inhaled fluticasone propionate and budesonide via metered-dose inhalers in adults with mild-to-moderate asthma. Br J Clin Res 1994;5:73-84.
92. Connolly A. A comparison of fluticasone propionate 100 μg twice daily with budesonide 200 μg twice daily via their respective powder devices in the treatment of mild asthma. Eur J Clin Res 1995;7:15-29.
93. Langdon CG, Capsey LJ. Fluticasone propionate and budesonide in adult asthmatics: a comparison using dry-powder inhaler devices. Br J Clin Res 1994;5:85-99.
94. Backman R, Pickering CAC, Baumgarten C, Huskisson SC. A comparison of fluticasone propionate via Diskus (Accuhaler) inhaler and budesonide via Turbuhaler inhaler in adult asthmatics (abstract). J Allergy Clin Immunol 1996;97:249.
95. Steinmetz K-O, Trautmann M. Efficacy of fluticasone propionate (0.5 mg daily) via MDI and budesonide (1.2 mg daily) via Turbuhaler in the treatment of steroid-naive asthmatics (abstract). Am J Respir Crit Care Med 1996;153:A338.
96. Ringdal N, Swinburn P, Backman R, Plaschke P, Sips AP, Kjaersgaard P, et al. A blinded comparison of fluticasone propionate with budesonide via powder devices in adult patients with moderate-to-severe asthma: a clinical evaluation. Mediators of Inflammation 1996;5:382-9.
97. Barnes NC, Hallett C, Harris TAJ. Clinical experience with fluticasone propionate in asthma: a meta-analysis of efficacy and systemic activity compared with budesonide and beclomethasone dipropionate at half the microgram dose or less. Respir Med 1998;92:95-104.
98. Namsirikul P, Chaisupamongkollarp S, Chantadisai N, Bamberg P. Comparison of inhaled budesonide with oral prednisolone at two dose-levels commonly used for the treatment of moderate asthma. Eur Respir J 1989;2:317-24.
99. Boe J, Bakke P, Rødølen T, Skovlund E, Gulsvik A. High-dose inhaled steroids in asthmatics: moderate efficacy gain and suppression of the hypothalamic-pituitary-adrenal (HPA) axis. Eur Respir J 1994;7:2179-84.
100. Selroos O, Backman R, Forsén K-O, Löfroos A-B, Niemistö M, Pietinalho A, et al. Clinical efficacy of budesonide Turbuhaler compared with that of beclomethasone dipropionate pMDI with volumatic spacer: a 2-year randomized study in 102 asthma patients. Allergy 1994;49:833-6.
101. Tjwa MKT. Budesonide inhaled via Turbuhaler: a more effective treatment for asthma than beclomethasone dipropionate via Rotahaler. Ann Allergy Asthma Immunol 1995;75:107-11.
102. Svendsen UG, Frølund L, Heinig JH, Madsen F, Nielsen NH, Weeke B. High-dose inhaled steroids in the management of asthma: a comparison of the effects of budesonide and beclomethasone dipropionate on pulmonary function, symptoms, bronchial responsiveness and the adrenal function. Allergy 1992;47:174-80.
103. Fabbri L, Burge PS, Croonenborgh L, Warlies F, Weeks B, Craccia A, et al. Comparison of fluticasone propionate with beclomethasone dipropionate in moderate to severe asthma treated for one year. Thorax 1993;48:817-23.
104. Ayres JG, Bateman ED, Lundbäck B, Harris TAJ. High dose fluticasone propionate, 1 mg daily, versus fluticasone propionate, 2 mg daily, or budesonide, 1.6 mg daily, in patients with chronic severe asthma. Eur Respir J 1995;8:579-86.
105. Hoekx JCM, Hedlin G, Pedersen W, Sorva R, Hollingworth K, Efthimiou J. Fluticasone propionate compared with budesonide: a double-blind trial in asthmatic children using powder devices at a dosage of 400 μ/day. Eur Respir J 1996;9:2263-72.
106. Condemi JJ, Chervinsky P, Goldstein MF, Ford LB, Berger WE, Ayars GH, et al. Fluticasone propionate powder administered through Diskhaler versus triamcinolone acetonide aerosol administered through metered-dose inhaler in patients with persistent asthma. Allergy Clin Immunol 1997;100:467-74.
107. Raphael GD, Baker JW, Chervinsky P, Grossman J, Goldstein MF, Rogenes PR, et al. Low dose fluticasone propionate (FP) is more effective than higher doses of beclomethasone dipropionate (BDP) in patients with mild to moderate asthma (abstract). J Allergy Clin Immunol 1998;101:A24.
108. Srebro SH, Weber HH, Rogenes PR, Edwards L, and the FP Clinical Study Group. Comparison of fluticasone propionate with flunisolide in patients with mild to moderate asthma (abstract). J Allergy Clin Immunol 1998;101:A27.
109. Friedman B, Rogenes PR, Srebro S, Edwards L, Johnson MC, and the FP Clinical Group. Patients with mild to moderate persistent asthma who were symptomatic despite taking inhaled corticesteroids achieved a greater improvement in pulmonary function with fluticasone propionate than with triamcinolone acetonide (abstract). J Allergy Clin Immunol 1998;101:A39.
110. Murray JJ, Friedman B, Chervinsky P, Fogarty C, Baker JW, Rogenes PR, et al. Asthma severity as a determinant for selecting appropriate doses of fluticasone propionate (FP) or beclomethasone dipropionate (BDP) [abstract]. J Allergy Clin Immunol 1998;101:A964.
111. Srebro SH, Rogenes PR, Edwards L, Lincourt WR. Comparison of efficacy and HPA effects of fluticasone propionate versus flunisolide in patients with mild to moderate asthma (abstract). Am J Respir Crit Care Med 1998;157:A406.
112. Murray JJ, Friedman B, Chervinsky P, Fogarty C, Baker JW, Rogenes PR, et al. Fluticasone propionate (FP) is more effective than higher doses of beclomethasone dipropionate (BDP) in patients with moderate asthma (abstract). Am J Respir Crit Care Med 1998;157:A407.
113. Cook D, Srebro SH, Rogenes PR, Rickard K, Edwards L, Johnson MC. A comparison of the safety and efficacy of fluticasone, triamcinolone, and fluticasone plus salmeterol in patients with mild to moderate asthma (abstract). Am J Respir Crit Care Med 1998;157:A416.